Shahneen Sandhu

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.

Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy, Scott Williams, Michael S Hofman

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic ..

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.

Andrei Gafita, Wolfgang P Fendler, Wang Hui, Shahneen Sandhu, Manuel Weber, Rouzbeh Esfandiari, Jeremie Calais, Isabel Rauscher, Hendrik Rathke, Robert Tauber, Ebrahim S Delpassand, Wolfgang A Weber, Ken Herrmann, Johannes Czernin, Matthias Eiber, Michael S Hofman

Journal article  |  2020  |  European Urology

The 177Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate ca..

Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone

Katie L Owen, Linden J Gearing, Damien J Zanker, Natasha K Brockwell, Weng Hua Khoo, Daniel L Roden, Marek Cmero, Stefano Mangiola, Matthew K Hong, Alex J Spurling, Michelle McDonald, Chia-Ling Chan, Anupama Pasam, Ruth J Lyons, Hendrika M Duivenvoorden, Andrew Ryan, Lisa M Butler, John M Mariadason, Tri Giang Phan, Vanessa M Hayes, et al.

Journal article  |  2020  |  EMBO reports

The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attributed to dormancy, a state in ..

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

Victoria Atkinson, Shahneen Sandhu, Geke Hospers, Georgina Long, Massimo Aglietta, Pier F Ferrucci, Skaiste Tulyte, Gian Carlo Antonini Cappellini, Virtudes Soriano, Sayed Ali, Alexandr Poprach, Alvydas Cesas, Delvys Rodriguez-Abreu, Mike Lau, Egbert de Jong, Philippe Legenne, Dara Stein, Brianna King, Johannes van Thienen

Journal article  |  2020  |  Melanoma Research

In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-agent BRAF inhibitors (BRAFi) i..

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.

Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia-Chi Lin, Chia-Jui Yen, Yee Chao, Bhumsuk Keam, Michael Jameson, Ming-Mo Hou, Yoon-Koo Kang, Ben Markman, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Shahneen Sandhu, Paula Barlow, Chi-Yuan Wu, et al.

Journal article  |  2020  |  Journal for ImmunoTherapy of Cancer

BACKGROUND: The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antit..

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-177-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Thang Sue-Ping, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott G Williams, Rod J Hicks, et al.

Journal article  |  2020  |  Journal of Nuclear Medicine

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation ..

High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.

Simon P Keam, Heloise Halse, Thu Nguyen, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David J Byrne, Sue Haupt, Georgina Ryland, Phillip K Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott G Williams, Paul J Neeson

Journal article  |  2020  |  Journal for ImmunoTherapy of Cancer

BACKGROUND: Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment and is commonly immune excluded with few inf..

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

Shahneen Sandhu, Catriona M McNeil, Patricia LoRusso, Manish R Patel, Omar Kabbarah, Chunze Li, Sandra Sanabria, W Michael Flanagan, Ru-Fang Yeh, Flavia Brunstein, Denise Nazzal, Rodney Hicks, Vanessa Lemahieu, Raymond Meng, Omid Hamid, Jeffrey R Infante

Journal article  |  2020  |  Investigational New Drugs

Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The anti..

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph Burgents, Wenting Wu, Alexander Kohlmann, Carrie A Adelman, Maha Hussain

Journal article  |  2020  |  New England Journal of Medicine

BACKGROUND: Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination rep..

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy.

CN Owen, AN Shoushtari, D Chauhan, DJ Palmieri, B Lee, MW Rohaan, J Mangana, V Atkinson, F Zaman, A Young, C Hoeller, P Hersey, R Dummer, MA Khattak, M Millward, SP Patel, A Haydon, DB Johnson, S Lo, CU Blank, et al.

Journal article  |  2020  |  Annals of Oncology

BACKGROUND: Anti-PD-1 antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25-..

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors.

Jenny H Lee, Alexander M Menzies, Matteo S Carlino, Ashleigh C McEvoy, Shahneen Sandhu, Alison M Weppler, Russell J Diefenbach, Sarah-Jane Dawson, Richard F Kefford, Michael J Millward, Zeyad Al-Ogaili, Thien Tra, Elin S Gray, Stephen Q Wong, Richard A Scolyer, Georgina V Long, Helen Rizos

Journal article  |  2020  |  Clinical Cancer Research

PURPOSE: Brain involvement occurs in majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ctDNA)..

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani, Medhat M Osman, Alison M Weppler, Roslyn Wallace, Anna Galligan, Arian Lasocki, Morgan O Hunter, Tim Akhurst, Michael S Hofman, Peter KH Lau, Damien Kee, George Au-Yeung, Shahneen Sandhu, Rodney J Hicks

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: We aimed to investigate the role of FDG-PET/CT in monitoring of response and immune-related adverse events (irAEs) follow..

Genome-wide plasma DNA methylation features of metastatic prostate cancer

Anjui Wu, Paolo Cremaschi, Daniel Wetterskog, Vincenza Conteduca, Gian Marco Franceschini, Dimitrios Kleftogiannis, Anuradha Jayaram, Shahneen Sandhu, Stephen Q Wong, Matteo Benelli, Samanta Salvi, Giorgia Gurioli, Andrew Feber, Mariana Buongermino Pereira, Anna Maria Wingate, Enrique Gonzalez-Billalebeitia, Ugo De Giorgi, Francesca Demichelis, Stefano Lise, Gerhardt Attard

Journal article  |  2020  |  Journal of Clinical Investigation

Tumor DNA circulates in the plasma of cancer patients admixed with DNA from noncancerous cells. The genomic landscape of plasma DN..

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.

John W Walker, Celeste Lebbé, Giovanni Grignani, Paul Nathan, Luc Dirix, Eyal Fenig, Paolo Antonio Ascierto, Shahneen Sandhu, Rodrigo Munhoz, Elena Benincasa, Sarah Flaskett, Josh Reed, Arne Engelsberg, Subramanian Hariharan, Vijay Kasturi

Journal article  |  2020  |  Journal for ImmunoTherapy of Cancer

BACKGROUND: Avelumab, a human anti-programmed death-ligand 1 immunoglobulin G1 monoclonal antibody, showed favorable efficacy and ..

Genomics of lethal prostate cancer at diagnosis and castration resistance

Joaquin Mateo, George Seed, Claudia Bertan, Pasquale Rescigno, David Dolling, Ines Figueiredo, Susana Miranda, Daniel Nava Rodrigues, Bora Gurel, Matthew Clarke, Mark Atkin, Rob Chandler, Carlo Messina, Semini Sumanasuriya, Diletta Bianchini, Maialen Barrero, Antonella Petermolo, Zafeiris Zafeiriou, Mariane Fontes, Raquel Perez-Lopez, et al.

Journal article  |  2020  |  The Journal of clinical investigation

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis

Pasquale Rescigno, David Dolling, Vincenza Conteduca, Mattia Rediti, Diletta Bianchini, Cristian Lolli, Michael Ong, Haoran Li, Aurelius G Omlin, Sabine Schmid, Orazio Caffo, Andrea Zivi, Carmel J Pezaro, Courtney Morley, David Olmos, Nuria Romero-Laorden, Elena Castro, Maria Saez, Niven Mehra, Stella Smeenk, et al.

Journal article  |  2020  |  European Urology Oncology

BACKGROUND: Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castr..

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial

Alexander MM Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stephane Dalle, Andrew Haydon, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus JM van den Eertwegh, et al.

Journal article  |  2020  |  JAMA Oncology

Importance: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibi..

Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study

Karolina Lisy, Julia Lai-Kwon, Andrew Ward, Shahneen Sandhu, Nadine A Kasparian, Julie Winstanley, Frances Boyle, David Gyorki, Karen Lacey, Jim Bishop, Michael Jefford

Journal article  |  2020  |  Quality of Life Research

PURPOSE: There is a lack of population-based data describing patient reported outcomes (PROs) in melanoma survivors which could gu..

Next-generation sequencing (NGS) of tumor tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience

Maha HA Hussain, Joaquin Mateo, Shahneen Kaur Sandhu, Karim Fizazi, Fred Saad, Neal D Shore, David Olmos, Claire Corcoran, Caroline Sibilla, Alexander Kohlmann, Carrie A Adelman, Julia Andrea Elvin, Carsten Dietrich Goessl, Joseph Burgents, Johann S De Bono

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study

Matthew Raymond Smith, Karim Fizazi, Shahneen Kaur Sandhu, William Kevin Kelly, Eleni Efstathiou, Primo Lara, Evan Y Yu, Daniel J George, Kim N Chi, Fred Saad, Jason Summa, Jamie M Freedman, Gary Mason, Byron M Espina, Eugene Zhu, Deborah S Ricci, Linda A Snyder, Jason S Simon, Shinta Cheng, Howard I Scher

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer

Mitchell Lawrence, David Clouston, Mark Frydenberg, Declan G Murphy, Carmel Jo Pezaro, David William Pook, Heather Thorne, Shahneen Kaur Sandhu, Roxanne Toivanen, Renea Taylor, Gail Risbridger

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Predicting radiation-induced immune trafficking and activation in localized prostate cancer

Scott Williams, Simon P Keam, Heloise Halse, Nguyen Thu, Catherine Mitchell, Franco Caramia, David Byrne, Sue Haupt, Georgina Ryland, Phillip K Darcy, Shahneen Kaur Sandhu, Piers Blombery, Ygal Haupt, Paul J Neeson

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

The tumor immune microenvironment of germline BRCA1/2 and sporadic prostate cancer

Anna S Trigos, Anupama Pasam, Patricia Diana Banks, Roslyn Wallace, Simon P Keam, Heather Thorne, Catherine Mitchell, David Clouston, Declan G Murphy, Nathan Lawrentschuk, Damien M Bolton, Daniel Moon, Elena Castro, David Olmos, Phillip K Darcy, Ygal Haupt, Scott Williams, David L Goode, Paul J Neeson, Shahneen Kaur Sandhu

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Kim N Chi, Dana E Rathkopf, Gerhardt Attard, Matthew Raymond Smith, Eleni Efstathiou, David Olmos, Eric Jay Small, Ji Youl Lee, Paul R Sieber, Curtis Dunshee, Deborah S Ricci, Jason S Simon, Xin Zhao, Nishi Kothari, Shinta Cheng, Shahneen Kaur Sandhu

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC)

Zhen Shi, Christopher Sweeney, Sergio Bracarda, Cora N Sternberg, Kim N Chi, David Olmos, Shahneen Kaur Sandhu, Christophe Massard, Nobuaki Matsubara, Marie-Laurence Harle-Yge, Malgorzata Nowicka, Matthew Wongchenko, Johann S De Bono

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol

Amelia Hyatt, Karla Gough, Andrew Murnane, George Au-Yeung, Tamara Dawson, Elizabeth Pearson, Haryana Dhillon, Shahneen Sandhu, Narelle Williams, Elizabeth Paton, Alex Billett, Anya Traill, Hayley Andersen, Victoria Beedle, Donna Milne

Journal article  |  2020  |  BMJ Open

INTRODUCTION: There is increasing evidence demonstrating the benefits of exercise in counteracting cancer treatment-related fatigu..

Efficacy of immune checkpoint inhibitors for in-transit melanoma

Emilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, Lumine Na, James Bozzi, Tavis Read, Victoria Atkinson, George Au-Yeung, Georgina Long, Grant A McArthur, Shahneen Sandhu, Robyn Saw, Euan Walpole, Alexander Menzies, Mark Smithers, David E Gyorki

Journal article  |  2020  |  Journal for ImmunoTherapy of Cancer

BACKGROUND: The efficacy of immune checkpoint inhibitors (ICI) in metastatic melanoma is well established. However, there are limi..

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese, Omi Parikh, Simon Crabb, Angus Robinson, Duncan McLaren, Alison Birtle, Jacob Tanguay, Susana Miranda, Ines Figueiredo, George Seed, Claudia Bertan, et al.

Journal article  |  2020  |  The Lancet Oncology

18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors Melanoma and Beyond

Rodney J Hicks, Amir Iravani, Shahneen Sandhu

Journal article  |  2020  |  PET Clinics

The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and..

E6AP Promotes a Metastatic Phenotype in Prostate Cancer

Cristina Gamell, Ivona Bandilovska, Twishi Gulati, Arielle Kogan, Syer Choon Lim, Zaklina Kovacevic, Elena A Takano, Clelia Timpone, Arjelle D Agupitan, Cassandra Litchfield, Giovanni Blandino, Lisa G Horvath, Stephen B Fox, Scott G Williams, Andrea Russo, Enzo Gallo, Piotr J Paul, Catherine Mitchell, Shahneen Sandhu, Simon P Keam, et al.

Journal article  |  2019  |  iScience

Although primary prostate cancer is largely curable, progression to metastatic disease is associated with very poor prognosis. E6A..

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.

Christina W Guo, Marliese Alexander, Youseph Dib, Peter KH Lau, Alison M Weppler, George Au-Yeung, Belinda Lee, Chloe Khoo, Don Mooney, Subodh B Joshi, Louise Creati, Shahneen Sandhu

Journal article  |  2019  |  European Journal of Cancer

Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have transformed the management of many malignancies. Alth..

Predicting radiation-induced immune trafficking and activation in localized prostate cancer

Simon Keam, Heloise Halse, Nguyen ThuNgoc, Catherine Mitchell, Franco Caramia, David Byrne, Sue Haupt, Georgina Ryland, Phillip Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott Williams, Paul Neeson

Conference Proceedings  |  2019  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

Australasian merkel cell carcinoma interest group (AMIGOs) - Improving the outlook for patients with Merkel cell carcinoma

Gerald Fogarty, Elizabeth Paton, Narelle Williams, Mark Shackleton, Jonathan Pincus, Shahneen Sandhu, Wen Xu

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

SK Sandhu, M Hussain, J Mateo, K Fizazi, F Saad, N Shore, K Chi, O Sartor, N Agarwal, D Olmos, A Thiery-Vuillemin, P Twardowski, N Mehra, C Goessl, J Kang, J Burgents, W Wu, A Kohlmann, C Adelman, J de Bono

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]

Shahneen Sandhu, Richard Tothill, Richard Scolyer, Alexander Guminski, Juergen Becker, Michael Poulsen, Victoria Atkinson, Paul Neeson, Mark Shackleton, David Pattison, Narelle Williams, Elizabeth Paton

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

PROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm)

Shahneen Sandhu, Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Kim Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph Burgents, Wenting Wu, Alexander Kohlmann, Carrie Adelman, Johann De Bono

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Scott G Williams, Rodney J Hicks, Michael S Hofman

Journal article  |  2019  |  European Urology Oncology

BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) ..

Avelumab treatment of metastatic merkel cell carcinoma (mMCC): Updated findings from Australian patients enrolled in an expanded access program(EAP)

Shahneen Sandhu, Vijay Kasturi, Alex Guminski, Christopher Steer, Victoria Atkinson, Ina Nordman, Peter Tobin, Josh Reed, Nuno Costa

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC)

AM Weppler, P Bhave, P De Ieso, M Chua, J Raleigh, A Hatzimihalis, A Gill, S Balachander, J Callahan, A Pattison, A Caneborg, G Au Yeung, G McArthur, RJ Hicks, R Tothill, SK Sandhu

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Marian L Burr, Christina E Sparbier, Kah Lok Chan, Yih-Chih Chan, Ariena Kersbergen, Enid YN Lam, Elizabeth Azidis-Yates, Dane Vassiliadis, Charles C Bell, Omer Gilan, Susan Jackson, Lavinia Tan, Stephen Q Wong, Sebastian Hollizeck, Ewa M Michalak, Hannah Siddle, Michael T McCabe, Rab K Prinjha, Glen R Guerra, Benjamin J Solomon, et al.

Journal article  |  2019  |  Cancer Cell

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

JS de Bono, K Fizazi, F Saad, N Shore, SK Sandhu, N Mehra, M Kolinsky, G Roubaud, M Ozguroglu, N Matsubara, C Gedye, YD Choi, C Padua, C Goessl, A Kohlmann, C Corcoran, CA Adelman, A Allen, J Burgents, M Hussain

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

MR Smith, SK Sandhu, WK Kelly, HI Scher, E Efstathiou, N Lara, EY Yu, DJ George, KN Chi, F Saad, J Summa, JM Freedman, GE Mason, E Zhu, D Ricci, JS Simon, S Cheng, K Fizazi

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)

R Lozano Mejorada, D Lorente, E Castro, D Bianchini, P Nombela, SK Sandhu, N Romero Laorden, Y Cendon, A Sharp, E Almagro Casado, MI Pacheco, P Rescigno, C Llacer, M Saez, L Rivera, F Vitrone, C Moreno, J Mateo, JS de Bono, D Olmos Hidalgo

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy

SK Sandhu, VG Atkinson, M Gonzalez Cao, T Medina, A Soria Rivas, I Caro, L Roberts, Y Song, Y Yan, GV Long

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases

S Siva, M Bressel, S Loi, S Sandhu, B Tran, J Mooi, J Lewin, A Azad, D Colyer, M Shaw, S Chander, K Cuff, S Wood, N Lawrentschuk, D Murphy, D Pryor

Conference Proceedings  |  2019  |  Journal of Thoracic Oncology

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

KN Chi, D Rathkopf, G Attard, MR Smith, E Efstathiou, D Olmos, EJ Small, JY Lee, P Sieber, C Dunshee, D Ricci, JS Simon, X Zhao, N Kothari, S Cheng, SK Sandhu

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)

GV Long, VG Atkinson, S Lo, SK Sandhu, M Brown, M Gonzalez, A Guminski, RA Scolyer, L Emmett, AM Menzies, GA McArthur

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

MR Stockler, AJ Martin, H Dhillon, ID Davis, KN Chi, S Chowdhury, LG Horvath, NJ Lawrence, GM Marx, J Mc Caffrey, R McDermott, SA North, F Parnis, DW Pook, MN Reaume, SK Sandhu, TH Tan, A Thomson, R Zielinski, CJ Sweeney

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Identification of single nucleotide variants using position-specific error estimation in deep sequencing data

Dimitrios Kleftogiannis, Marco Punta, Anuradha Jayaram, Shahneen Sandhu, Stephen Q Wong, Delila Gasi Tandefelt, Vincenza Conteduca, Daniel Wetterskog, Gerhardt Attard, Stefano Lise

Journal article  |  2019  |  BMC Medical Genomics

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer

Laura H Porter, Mitchell G Lawrence, Hong Wang, Ashlee K Clark, Andrew Bakshi, Daisuke Obinata, David Goode, Melissa Papargiris, undefined Mural, David Clouston, Andrew Ryan, Sam Norden, Eva Corey, Peter S Nelson, John T Isaacs, Jeremy Grummet, John Kourambas, Shahneen Sandhu, Declan G Murphy, David Pook, et al.

Journal article  |  2019  |  The Prostate

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

Julia Lai-Kwon, Chloe Khoo, Serigne Lo, Donna Milne, Mustafa Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford

Journal article  |  2019  |  Journal of Cancer Survivorship

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D Davis, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, et al.

Journal article  |  2019  |  New England Journal of Medicine

Immune Profiling of Primary Prostate Cancer Arising in Men with and Without Germline DNA Repair Defects

Shahneen Sandhu, Anna Trigos, Anu Pasam, Patricia Banks, Simon Keam, Heather Thorn, Catherine Mitchell, David Clouston, Declan Murphy, Damien Bolton, Phil Darcy, Ygal Haupt, Scot Williams, David Goode, Paul Neeson

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Alexander MM Eggermont, Christian U Blank, Mario Mandala, Georgina Long, Victoria G Atkinson, Stephane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus JM van den Eertwegh, et al.

Journal article  |  2019  |  European Journal of Cancer

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone -sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Christopher Sweeney, Andrew James Martin, Robert Richard Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Kaur Sandhu, M Neil Reaume, David William Pook, Francis Parnis, Scott A North, Ray McDermott, John McCaffrey, Gavin M Marx, Nicola Jane Lawrence, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim N Chi, Martin R Stockler, Ian D Davis

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics

Declan G Murphy, Arun A Azad, Shahneen Sandhu, John Violet, Michael S Hofman

Journal article  |  2019  |  European Urology

Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC).

Alison Weppler, Prachi Bhave, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony J Gill, Shiva Balachander, Jason Callahan, Andrew Pattison, Margaret Chua, George Au-Yeung, Grant A McArthur, Rodney J Hicks, Richard Tothill, Shahneen Kaur Sandhu

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.

Alexander MM Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stephane Dalle, Andrew Mark Haydon, Mikhail Lichinitser, Muhammad Khattak, Matteo S Carlino, Shahneen Kaur Sandhu, Susana Puig, Paolo Antonio Ascierto, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Alexander Christopher Jonathan Van Akkooi, Caroline Robert, Stefan Suciu

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.

Emilia Nan Tie, Julia Elizabeth Lai-Kwon, Lumine Na, Michael Alexander Rtshiladze, James Bozzi, Tavis Read, Victoria Atkinson, George Au-Yeung, Georgina V Long, Grant A McArthur, Shahneen Kaur Sandhu, Robyn Saw, Euan Thomas Walpole, Alexander M Menzies, B Mark Smithers, David E Gyorki

Conference Proceedings  |  2019  |  JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Funda Meric-Bernstam, Shahneen Kaur Sandhu, Omid Hamid, Anna Spreafico, Stefan Kasper, Reinhard Dummer, Toshio Shimizu, Neeltje Steeghs, Nancy Lewis, Craig C Talluto, Sinead Dolan, Andrew Bean, Robert Brown, Damian Trujillo, Nitya Nair, Jason J Luke

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

CA045-001: A phase Ill, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).

Nikhil I Khushalani, Adi Diab, Paolo Antonio Ascierto, James MG Larkin, Shahneen Kaur Sandhu, Mario Sznol, Henry B Koon, Anthony Jarkowski, Ming Zhou, Rui Wang, Gaurav Bajaj, Georgina V Long

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel

Elin S Gray, Tom Witkowski, Michelle Pereira, Leslie Calapre, Karl Herron, Darryl Irwin, Brett Chapman, Muhammad A Khattak, Jeanette Raleigh, Athena Hatzimihalis, Jonathan Cebon, Shahneen Sandhu, Grant A McArthur, Michael Millward, Melanie Ziman, Alexander Dobrovic, Stephen Q Wong

Journal article  |  2019  |  The Journal of Molecular Diagnostics

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni, N Dhomen, P Middlehurst, A Wallace, J Raleigh, A Hatzimihalis, MA Henderson, M Shackleton, A Haydon, V Mar, DE Gyorki, D Oudit, MA Dawson, RJ Hicks, P Lorigan, et al.

Journal article  |  2019  |  Annals of Oncology

BACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify pa..

Response assessment and immune-related adverse events as detected by FDG PET/CT in patients treated with combined CTLA-4 and PD-1 checkpoint inhibitors as first line therapy in advanced melanoma

Amir Iravani, Medhat Osman, Michael Hofman, Alison Weppler, George Au-Yeung, Shahneen Sandhu, Rodney Hicks

Conference Proceedings  |  2019  |  JOURNAL OF NUCLEAR MEDICINE

Dosimetry of Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman

Journal article  |  2019  |  Journal of Nuclear Medicine

Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC

S Siva, M Bressel, S Sandhu, B Tran, J Mooi, J Lewin, S Loi, G Toner, D Moon, J Goad, M Shaw, S Chander, T Eade, A Guminski, D Jayamanne, D Pryor, K Cuff, S Wood, N Lawrentschuk, D Murphy

Conference Proceedings  |  2019  |  Radiotherapy and Oncology

PATTERNS AND PREVALENCE OF IMMUNE-RELATED ADVERSE EVENTS AS DETECTED WITH FDG PET/CT IN PATIENTS TREATED WITH COMBINED CTLA-4 AND PD-1 INHIBITOR AS FIRST-LINE THERAPY FOR ADVANCED MELANOMA

A Iravani, MM Osman, MS Hofman, A Weppler, G Au-Yeung, S Sandhu, RJ Hicks

Conference Proceedings  |  2019  |  INTERNAL MEDICINE JOURNAL

Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target

Rachel S Lee, Luxi Zhang, Adeline Berger, Mitchell G Lawrence, Jiangning Song, Birunthi Niranjan, Rebecca G Davies, Natalie L Lister, Shahneen K Sandhu, Mark A Rubin, Gail P Risbridger, Renea A Taylor, David S Rickman, Lisa G Horvath, Roger J Daly

Journal article  |  2019  |  Neoplasia

Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.

Scott Williams, Simon Keam, Heloise Halse, Catherine Mitchell, Franco Caramia, David Byrne, Sue Haupt, Georgina Ryland, Phil Darcy, Shahneen Kaur Sandhu, Piers Blombery, Ygal Haupt, Paul J Neeson

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).

Kobe Chi Yung Yuen, Tran Ben, Peter Gibbs, Angelyn Anton, Sanjeev Mariathasan, Shahneen Kaur Sandhu, Edward Ernest Kadel

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Matthew Raymond Smith, Shahneen Kaur Sandhu, William Kevin Kelly, Howard I Scher, Eleni Efstathiou, Primo Lara, Evan Y Yu, Daniel J George, Kim N Chi, Jason Summa, Nishi Kothari, Xin Zhao, Byron M Espina, Deborah S Ricci, Jason S Simon, Namphuong Tran, Karim Fizazi

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Michael Hofman, John A Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Timothy J Akhurst, Jennifer Mooi, Christina Guo, Ben Tran, Price Jackson, Mark Scalzo, Peter Eu, Scott Williams, Shahneen Kaur Sandhu

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Patricia D Banks, Arian Lasocki, Peter KH Lau, Shahneen Sandhu, Grant McArthur, Mark Shackleton

Journal article  |  2019  |  Health Science Reports

Background: Brain metastases are common in advanced melanoma and often necessitate corticosteroids such as dexamethasone to contro..

Microbiome transplantation and modulation of immune related adverse events.

Olivia C Smibert, Christina W Guo, Chloe Khoo, KA Thursky, Shahneen Sandhu, Monica A Slavin

Journal article  |  2019  |  EClinicalMedicine

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

Emma L Mitchell, Peter Kar Han Lau, Chloe Khoo, David Liew, Jessica Leung, Bonnia Liu, Adam Rischin, Albert G Frauman, Damien Kee, Kortnye Smith, Benjamin Brady, Danny Rischin, Andrew Gibson, Linda Mileshkin, Oliver Klein, Andrew Weickhardt, Surein Arulananda, Mark Shackleton, Grant McArthur, Andrew Ostor, et al.

Journal article  |  2018  |  European Journal of Cancer

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy

Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Patrick Terheyden, Kent C Shih, Isaac Brownell, Celeste Lebbe, Karl D Lewis, Gerald P Linette, Michele Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P D'Angelo

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Avelumab treatment of Australian patients with metastatic Merkel cell carcinoma (mMCC): Experience from an expanded access program (EAP)

Tom van Hagen, Shahneen Sandhu, Vijay Kasturi, Christopher Steer, Chloe Khoo, Ina Nordman, Meliessa Hennessy, Steven Hildemann, Josh Reed, Subramanian Hariharan

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors

JE Lai-Kwon, C Khoo, S Lo, D Milne, M Mohamed, J Raleigh, K Smith, K Lisy, SK Sandhu, M Jefford

Conference Proceedings  |  2018  |  Annals of Oncology

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Mitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, Luke A Selth, Stephen Q Wong, Laura H Porter, Natalie Lister, David Pook, Carmel J Pezaro, David L Goode, Richard J Rebello, Ashlee K Clark, Melissa Papargiris, Jenna Van Gramberg, Adrienne R Hanson, Patricia Banks, Hong Wang, Birunthi Niranjan, Shivakumar Keerthikumar, Shelley Hedwards, et al.

Journal article  |  2018  |  European Urology

Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma

L Tan, SK Sandhu, R Lee, J Li, J Callahan, J Raleigh, A Hatzimihalis, P Middlehurst, M Henderson, M Shackleton, A Haydon, D Gyorki, D Oudit, RJ Hicks, P Lorigan, GA McArthur, R Marais, SQ Wong, S-J Dawson

Conference Proceedings  |  2018  |  Annals of Oncology

Mortality due to immunotherapy related hepatitis

Prachi Bhave, Andrew Buckle, Shahneen Sandhu, Siddharth Sood

Journal article  |  2018  |  Journal of Hepatology

Voxel based dosimetry of Lu-177-PSMA-617 within a prospective clinical trial: Whole body tumour dosimetry and correlations with pre-therapeutic imaging and biochemical outcomes

JA Violet, P Jackson, J Ferdinandus, S Thang, S Sandhu, M Scalzo, RJ Hicks, MS Hofman

Conference Proceedings  |  2018  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial

C Coens, A Bottomley, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, A Haydon, M Lichinitser, A Khattak, MS Carlino, SK Sandhu, J Larkin, S Puig Sarda, PA Ascierto, D Schadendorf, N Ibrahim, S Suciu, C Robert, AMM Eggermont

Conference Proceedings  |  2018  |  Annals of Oncology

Diabetes associated with immune checkpoint inhibition: presentation and management challenges

A Galligan, W Xu, S Fourlanos, A Nankervis, C Chiang, AM Mant, P Parente, D Rischin, B Krishnamurthy, S Sandhu, PG Colman

Journal article  |  2018  |  Diabetic Medicine

Gastrointestinal complications of melanoma immunotherapy in a large Australian cohort

A Buckle, R Vaughan, A Weppler, S Sandhu, A Boussioutas

Conference Proceedings  |  2018  |  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

[Lu-177]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply

Michael S Hofman, John Violet, Rodney J Hicks, Shahneen Sandhu

Journal article  |  2018  |  The Lancet Oncology

The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer.

Richard Rebello, Eric Kusnadi, Donald P Cameron, Pearson Helen, Denis Drygin, Shahneen Sandhu, Gail Risbridger, Richard B Pearson, Ross D Hannan, Luc Furic

Conference Proceedings  |  2018  |  CANCER RESEARCH

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma

H Halse, AJ Colebatch, P Petrone, MA Henderson, JK Mills, H Snow, JA Westwood, S Sandhu, JM Raleigh, A Behren, J Cebon, PK Darcy, MH Kershaw, GA McArthur, DE Gyorki, PJ Neeson

Journal article  |  2018  |  Scientific Reports

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma

J Lewin, L Sayers, D Kee, I Walpole, A Sanelli, L te Marvelde, A Herschtal, J Spillane, D Gyorki, D Speakman, V Estall, S Donahoe, M Pohl, K Pope, M Chua, S Sandhu, GA McArthur, CJ McCormack, M Henderson, RJ Hicks, et al.

Journal article  |  2018  |  Annals of Oncology

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial

Alexander M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stephane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Michele Maio, Alfonsus J van den Eertwegh, et al.

Conference Proceedings  |  2018  |  Clinical Trials

[Lu-177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu

Journal article  |  2018  |  The Lancet Oncology

Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

Shahneen Kaur Sandhu, John A Violet, Justin Ferdinandus, Sue-Ping Thang, Amir Iravani, Christina Guo, Grace Kong, Aravind Ravi Kumar, Timothy J Akhurst, Alexis Beaulieu, Declan G Murphy, Jennifer Mooi, Ben Tran, Guy C Toner, Scott Williams, Rodney J Hicks, Michael Hofman

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Early changes in PSA and association with outcomes in mCRPC patients.

Pasquale Rescigno, David Dolling, Mattia Rediti, Vincenza Conteduca, Michael Ong, Haoran Li, Aurelius Gabriel Omlin, Sabine Schmid, Orazio Caffo, Andrea Zivi, Carmel Jo Pezaro, Courtney Morley, Nuria Romero-Laorden, Maria Isabel Saez, Niven Mehra, Spyridon Sideris, Shahneen Kaur Sandhu, Cora N Sternberg, Ugo De Giorgi, Johann S De Bono

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).

Chloe Chia Hoey Khoo, Julia Elizabeth Lai-Kwon, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Maureen Smith, Michael Jefford, Shahneen Kaur Sandhu

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT)

Julia Elizabeth Lai-Kwon, Chloe Chia Hoey Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Maureen Smith, Shahneen Kaur Sandhu, Michael Jefford

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP)

John Walker, Vijay Kasturi, Celeste Lebbe, Shahneen Kaur Sandhu, Giovanni Grignani, Meliessa G Hennessy, Steven Hildemann, Josh Reed, Subramanian Hariharan

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

The poor outcome of patients with mCRPC whom were deemed ineligible for PSMA theranostics based on molecular imaging characteristics.

Sue Ping Thang, John A Violet, Shahneen Kaur Sandhu, Amir Iravani, Timothy J Akhurst, Aravind Ravi Kumar, Grace Kong, Scott Williams, Rodney J Hicks, Michael Hofman, Michael Hofman

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander MM Eggermont, Christian U Blank, Mario Mandala, Georgina Long, Victoria Atkinson, Stephane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Michele Maio, Alfonsus JM van den Eertwegh, et al.

Journal article  |  2018  |  New England Journal of Medicine

Prognostic value of baseline imaging parameters prior to therapy with Lu-177-PSMA-617

Justin Ferdinandus, Sue Ping Thang, John Violet, Rodney Hicks, Shahneen Sandhu, Michael Hofman

Conference Proceedings  |  2018  |  JOURNAL OF NUCLEAR MEDICINE

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander D Guminski, Michael P Brown, James S Wilmott, Jarem Edwards, Maria Gonzalez, Richard A Scolyer, Alexander M Menzies, Grant A McArthur

Journal article  |  2018  |  The Lancet Oncology

High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial

Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks

Conference Proceedings  |  2018  |  JOURNAL OF NUCLEAR MEDICINE

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study

Joaquin Mateo, Heather H Cheng, Himisha Beltran, David Dolling, Wen Xu, Colin C Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Perez-Lopez, Verena Sailer, Michael Kolinsky, Ada Balasopoulou, Claudia Bertan, David M Nanus, Scott T Tagawa, Heather Thorne, Bruce Montgomery, Suzanne Carreira, Shahneen Sandhu, Mark A Rubin, et al.

Journal article  |  2018  |  European Urology

Managing toxicities of immune checkpoint inhibitors

Christina Guo, Shahneen Sandhu

Journal article  |  2018  |  CANCER FORUM

Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment Reply

Serigne N Lo, Shahneen Sandhu

Journal article  |  2018  |  Journal of Clinical Oncology

Prostate-specific membrane antigen theranostics: therapy with lutetium-177

Justin Ferdinandus, John Violet, Shahneen Sandhu, Michael S Hofman

Journal article  |  2018  |  Current Opinion in Urology

Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.

Shahneen Kaur Sandhu, Andrew Graham Hill, Hui Kong Gan, Michael Friedlander, Mark Voskoboynik, Paula Barlow, Amanda Rose Townsend, James Song, Yun Zhang, Zhirong Shen, Qinzhou Qi, Jayesh Desai

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.

Andrew James Weickhardt, Farshad Foroudi, Shomik Sengupta, Laura Galletta, Alan Herschtal, Peter S Grimison, Nitya Patanjali, Siobhan Ng, Colin Tang, Robert Goodwin, Elizabeth J Hovey, Tom Jarvis, Colin Chen, Shahneen Kaur Sandhu, Keen Hun Tai, Nathan Lawrentschuk, Ian D Davis

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.

Joaquin Mateo, Heather H Cheng, Himisha Beltran, David Dolling, Wen Xu, Colin Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Perez-Lopez, Verena Sailer, Michael Paul Kolinsky, Ada Balasopoulou, Claudia Bertan, Suzanne Carreira, Heather Thorne, Robert B Montgomery, Shahneen Kaur Sandhu, Mark A Rubin, Peter Nelson, Johann S De Bono

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Matteo S Carlino, Shahneen Sandhu

Journal article  |  2017  |  Journal of Clinical Oncology

When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'

David E Gyorki, Andrew Barbour, Mark Hanikeri, Victoria Mar, Shahneen Sandhu, John F Thompson

Journal article  |  2017  |  Australasian Journal of Dermatology

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.

George Seed, Wei Yuan, Joaquin Mateo, Suzanne Carreira, Claudia Bertan, Maryou Lambros, Gunther Boysen, Roberta Ferraldeschi, Susana Miranda, Ines Figueiredo, Ruth Riisnaes, Mateus Crespo, Daniel Nava Rodrigues, Eric Talevich, Dan R Robinson, Lakshmi P Kunju, Yi-Mi Wu, Robert Lonigro, Shahneen Sandhu, Arul M Chinnaiyan, et al.

Journal article  |  2017  |  Clinical Cancer Research

Purpose: Precise detection of copy number aberrations (CNA) from tumor biopsies is critically important to the treatment of metast..

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Jane Goodall, Joaquin Mateo, Wei Yuan, Helen Mossop, Nuria Porta, Susana Miranda, Raquel Perez-Lopez, David Dolling, Dan R Robinson, Shahneen Sandhu, Gemma Fowler, Berni Ebbs, Penny Flohr, George Seed, Daniel Nava Rodrigues, Gunther Boysen, Claudia Bertan, Mark Atkin, Matthew Clarke, Mateus Crespo, et al.

Journal article  |  2017  |  Cancer Discovery

Relevance of DNA damage repair in the management of prostate cancer

Patricia Banks, Wen Xu, Declan Murphy, Paul James, Shahneen Sandhu

Journal article  |  2017  |  Current Problems in Cancer

E6AP promotes prostate cancer by reducing p27 expression

Dinesh Raghu, Piotr Jan Paul, Twishi Gulati, Siddhartha Deb, Christine Khoo, Andrea Russo, Enzo Gallo, Giovanni Blandino, Ai-Leen Chan, Elena Takano, Shahneen K Sandhu, Stephen B Fox, Scott Williams, Sue Haupt, Cristina Gamell, Ygal Haupt

Journal article  |  2017  |  Oncotarget

Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection

Alastair D Lamb, Mitchell G Lawrence, Shahneen Sandhu

Journal article  |  2017  |  European Urology

Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).

Stergios J Moschos, Shahneen Kaur Sandhu, Karl D Lewis, Ryan J Sullivan, Douglas Buckner Johnson, Yilong Zhang, Erik Rasmussen, Haby A Henary, Georgina V Long

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).

Georgina V Long, Victoria Atkinson, Alexander M Menzies, Serigne Lo, Alexander David Guminski, Michael Paul Brown, Maria Magdalena Gonzalez, Katrina Diamante, Shahneen Kaur Sandhu, Richard A Scolyer, Louise Emmett, Grant A McArthur

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer

Declan G Murphy, Gail P Risbridger, Robert G Bristow, Shahneen Sandhu

Journal article  |  2017  |  European Urology

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, JJ Park, JL McQuade, AN Shoushtari, KK Tsai, Z Eroglu, O Klein, JC Hassel, JA Sosman, A Guminski, RJ Sullivan, A Ribas, MS Carlino, MA Davies, SK Sandhu, GV Long

Journal article  |  2017  |  Annals of Oncology

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma

Stephen Q Wong, Jeanette M Raleigh, Jason Callahan, Ismael A Vergara, Sarah Ftouni, Athena Hatzimihalis, Andrew J Colebatch, Jason Li, Timothy Semple, Kenneth Doig, Christopher Mintoff, Devbarna Sinha, Paul Yeh, Maria Joao Silva, Kathryn Alsop, Heather Thorne, David D Bowtell, David E Gyorki, Gisela Mir Arnau, Carleen Cullinane, et al.

Journal article  |  2017  |  JCO Precision Oncology

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

Richard J Rebello, Eric Kusnadi, Donald P Cameron, Helen B Pearson, Analia Lesmana, Jennifer R Devlin, Denis Drygin, Ashlee K Clark, Laura Porter, John Pedersen, Shahneen Sandhu, Gail P Risbridger, Richard B Pearson, Ross D Hannan, Luc Furic

Journal article  |  2016  |  Clinical Cancer Research

A community-based model of rapid autopsy in end-stage cancer patients

Kathryn Alsop, Heather Thorne, Shahneen Sandhu, Anne Hamilton, Christopher Mintoff, Elizabeth Christie, Odette Spruyt, Scott Williams, Orla McNally, Linda Mileshkin, Sumitra Ananda, Julene Hallo, Sherene Loi, Clare Scott, Peter Savas, Lisa Devereux, Patricia O'Brien, Sameera Gunawardena, Clare Hampson, Kate Strachan, et al.

Journal article  |  2016  |  Nature Biotechnology

Use of vemurafenib in a patient unable to swallow whole

Brett Janson, James Whittle, Kate Witney, Kate Moodie, Jason Callahan, Shahneen Sandhu

Journal article  |  2016  |  Journal of Oncology Pharmacy Practice

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

Giandomenico Roviello, Sandra Sigala, Shahneen Sandhu, Alberto Bonetta, Maria Rosa Cappelletti, Laura Zanotti, Alberto Bottini, Cora N Sternberg, Stephen B Fox, Daniele Generali

Journal article  |  2016  |  European Journal of Cancer

Recent Insights and Advances in the Management of Merkel Cell Carcinoma

Patricia D Banks, Shahneen Sandhu, David E Gyorki, Meredith L Johnston, Danny Rischin

Journal article  |  2016  |  Journal of Oncology Practice

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma

B Lee, A Wong, D Kee, P Neeson, M Shackleton, G McArthur, S Sandhu

Journal article  |  2016  |  Annals of Oncology

Integration of Immuno-Oncology and Palliative Care

Annie Wong, Sonia Fullerton, Odette Spruyt, Benjamin Brady, Grant McArthur, Shahneen Sandhu

Journal article  |  2016  |  Journal of Clinical Oncology

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

Stephen Q Wong, Kelly Waldeck, Ismael A Vergara, Jan Schroeder, Jason Madore, James S Wilmott, Andrew J Colebatch, Ricardo De Paoli-Iseppi, Jason Li, Richard Lupat, Timothy Semple, Gisela Mir Arnau, Andrew Fellowes, J Helen Leonard, George Hruby, Graham J Mann, John F Thompson, Carleen Cullinane, Meredith Johnston, Mark Shackleton, et al.

Journal article  |  2015  |  Cancer Res

Sentinel node biopsy for melanoma: The medical oncology perspective

Alexander M Menzies, Victoria G Atkinson, Michael P Brown, Matteo S Carlino, Jonathan Cebon, Alexander Guminski, Richard F Kefford, Georgina V Long, Grant McArthur, Catriona M McNeil, Michael Millward, Shahneen Sandhu

Journal article  |  2015  |  Australian Family Physician

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

S Kamel, L Horton, L Ysebaert, M Levade, K Burbury, S Tan, M Cole-Sinclair, J Reynolds, R Filshie, S Schischka, A Khot, S Sandhu, MJ Keating, H Nandurkar, CS Tam

Journal article  |  2015  |  Leukemia

Cell cycle control as a promising target in melanoma

Belinda Lee, Shahneen Sandhu, Grant McArthur

Journal article  |  2015  |  Current Opinion in Oncology

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Samantha E Bowyer, Aparna D Rao, Megan Lyle, Shahneen Sandhu, Georgina V Long, Grant A McArthur, Jeanette M Raleigh, Rodney J Hicks, Michael Millward

Journal article  |  2014  |  Melanoma Research

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin, Nathan Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L Carpenter, Robert Iannone, Stan B Kaye, et al.

Journal article  |  2013  |  The Lancet Oncology